Estimating the US burden of methicillin-resistant Staphylococcus aureus (MRSA) infections is important for planning and tracking success of prevention strategies. OBJECTIVE To describe updated national estimates and characteristics of health care-and community-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in 2011. DESIGN, SETTING, AND PARTICIPANTS Active laboratory-based case finding identified MRSA cultures in 9 US metropolitan areas from 2005 through 2011. Invasive infections (MRSA cultured from normally sterile body sites) were classified as health care-associated community-onset (HACO) infections (cultured Յ3 days after admission and/or prior year dialysis, hospitalization, surgery, long-term care residence, or central vascular catheter presence Յ2 days before culture); hospital-onset infections (cultured >3 days after admission); or community-associated infections if no other criteria were met. National estimates were adjusted using US census and US Renal Data System data. MAIN OUTCOMES AND MEASURES National estimates of invasive HACO, hospital-onset, and community-associated MRSA infections using US census and US Renal Data System data as the denominator. RESULTS An estimated 80 461 (95% CI, 69 515-93 914) invasive MRSA infections occurred nationally in 2011. Of these, 48 353 (95% CI, 40 195-58 642) were HACO infections; 14 156 (95% CI, 10 096-20 440) were hospital-onset infections; and 16 560 (95% CI, 12 806-21 811) were community-associated infections. Since 2005, adjusted national estimated incidence rates decreased among HACO infections by 27.7% and hospital-onset infections decreased by 54.2%; community-associated infections decreased by only 5.0%. Among recently hospitalized community-onset (nondialysis) infections, 64% occurred 3 months or less after discharge, and 32% of these were admitted from long-term care facilities. CONCLUSIONS AND RELEVANCE An estimated 30 800 fewer invasive MRSA infections occurred in the United States in 2011 compared with 2005; in 2011 fewer infections occurred among patients during hospitalization than among persons in the community without recent health care exposures. Effective strategies for preventing infections outside acute care settings will have the greatest impact on further reducing invasive MRSA infections nationally.

This cross-sectional study evaluates the appropriateness of antimicrobial use for hospitalized patients treated for community-acquired pneumonia or a urinary tract infection present at admission or for patients who had received fluoroquinolone or intravenous vancomycin treatment.

IMPORTANCECurrent information on the characteristics of patients who develop sepsis may help in identifying opportunities to improve outcomes. Most recent studies of sepsis epidemiology have focused on changes in incidence or have used administrative data sets that provided limited patientlevel data. OBJECTIVE To describe sepsis epidemiology in adults. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study reviewed the medical records, death certificates, and hospital discharge data of adult patients with sepsis or septic shock who were discharged from the hospital between October 1, 2014, and September 30, 2015. The convenience sample was obtained from hospitals in the Centers for Disease Control and Prevention Emerging Infections Program in 10 states (California,

A r t i c l e A m e n d m e n t s 3 7 2 3

Purpose To estimate the association between diabetes mellitus (DM) and all-cause mortality during tuberculosis (TB) treatment. Methods From 2009 to 2012 a retrospective cohort study among reported TB cases in Georgia was conducted. Patients aged ≥16 years were classified by DM and HIV status at time of TB diagnosis and followed during TB treatment to assess mortality. Hazard ratios (HR) were used to estimate the association between DM and death. Results Among 1,325 patients with TB disease, 151 (11.4%) had DM, 147 (11.1%) were HIV-infected, and 7 (0.5%) had both DM and HIV. Patients with TB-DM were more likely to have cavitary lung disease compared to those with TB alone (51.0% vs. 34.7%) and those with TB-HIV were more likely to have military/disseminated disease (12.9% vs. 3.4%) and resistance to rifampin or isoniazid (21.8% vs. 9.0%) compared with those without HIV infection (p<0.05). In multivariable analysis, DM was not associated with death during TB treatment (HR 1.22, 95% CI 0.70–2.12) or any death (aOR 1.05, 95% CI 0.60–1.84). Conclusions Among TB patients in Georgia, the prevalence of co-morbid DM and co-infection with HIV was nearly identical. In adjusted models, TB patients with DM did not have increased risk of all-cause mortality.